The Limited Partners’ Handbook for Investing in AI-Enabled Healthcare

Article written by?Doug Nissinoff

[email protected]

For more insights on the intersection of AI and healthcare,?visit our website ?and?subscribe ?for regular updates.?

Introduction

The Evolution of Healthcare: A Brief Overview

In a world where every sector is constantly evolving, the healthcare industry stands as a testament to human ingenuity and resilience. From the era of rudimentary medical procedures to today's technologically advanced medical ecosystems, the sector has seen exponential growth and innovation. Today, we stand at the precipice of yet another revolution in healthcare, where integration with technology promises not just enhanced efficiencies but a paradigm shift in how we approach wellness and disease management. This evolution beckons stakeholders to be a part of a journey that reshapes the future of healthcare, bringing forth unparalleled opportunities and advancements.

The Rise of Artificial Intelligence in Healthcare

As we navigate this transformative era, artificial intelligence (AI) emerges as the beacon leading the way. AI has seamlessly woven itself into the fabric of healthcare, promising to be the catalyst that accelerates innovation to unprecedented heights. From facilitating early disease detection through intricate algorithms to personalizing medicine with predictive analytics, AI serves as a linchpin in the current healthcare revolution. It holds the potential to decode complex biological data, streamline clinical trials, and foster the development of groundbreaking therapies. The convergence of healthcare and AI signifies a promising frontier, opening doors to solutions that were once thought to be beyond our reach.?

The Necessity of Strategic Investments

While the potentials are immense, the path to actualizing them relies heavily on well-directed investments. The nexus of AI and healthcare presents a fertile ground for investors seeking to cultivate innovation and fuel the next wave of industry leaders. As the landscape burgeons, the need for strategic investments cannot be overstated. Aligning financial resources with pioneering enterprises can not only propel the industry forward but also carve out avenues for sustainable growth and remarkable returns. In this dynamic ecosystem, limited partners (LPs) play a pivotal role, fostering environments where creativity meets capital, and dreams transform into tangible realities. At Intelligence Ventures, we stand as a conduit to this promising future, bridging the gap between visionary entrepreneurs and astute investors, dedicated to nurturing the seeds of tomorrow's healthcare marvels.

Section 1: Understanding the Landscape

The Current State of the AI and Healthcare Market

In the fast-evolving sphere of healthcare, we are witnessing an explosive growth characterized by a significant influx of AI applications across various sectors including biotech, pharma, medtech, diagnostics, and even within SaaS companies. At Intelligence Ventures, we are fully immersed in this dynamic ecosystem, seeking to harness the vast array of opportunities that span across these vital industry verticals.

Notably, generative AI has reached a pivotal point of critical mass, a testimony to the remarkable success of ChatGPT, which amassed 100 million users within a few months of its launch in November 2022 [4] . This milestone also signals the readiness of the healthcare sector to welcome AI applications with open arms.

To underline the market's robust trajectory, recent reports from Morgan Stanley [1] resonate with our observations. A staggering 94% of healthcare companies have embraced AI/ML in various capacities, reflecting a burgeoning trend that seems poised for further growth. Moreover, the industry's budget allocation towards these technologies is anticipated to nearly double, escalating from 5.7% in 2022 to a promising 10.5% by 2024.?

Furthermore, the FDA's increasing receptiveness towards AI and ML components is telling. In 2021 alone, the administration witnessed more than a hundred drug and biologic applications that incorporated AI/ML elements, representing a significant jump from just 14 in the previous year. This rise not only underscores the growing reliance on AI/ML technologies but also signals a potential revolution along the entire healthcare vertical, starting with shortened R&D timelines and reduced expenditures, and ending with drastically improved patient outcomes.????

?However, it's worth noting that we are only scratching the surface. Despite the recent advances in generative AI, a mere 24% of medical devices are currently utilizing AI/ML technologies, presenting a vast and untapped landscape rife with opportunities. Intelligence Ventures stands at the forefront of the sector, ready to capitalize on the untapped potential by identifying the Founders and their innovations that promise to redefine the contours of the healthcare industry.

Identifying the Key Players: Startups and Established Firms

Healthcare companies are increasingly seeking partnerships with tech giants to foster the integration of artificial intelligence into their frameworks. These collaborations not only aim to enhance efficiency but are reshaping the very fabric of the healthcare industry, paving the way for more personalized, data-driven, and accessible healthcare solutions.

?Let's delve deeper into identifying these key players in the AI arena who are at the forefront of this integration:

1. Google/DeepMind

Google, through its AI research lab, DeepMind, is an incumbent?in the field of AI. DeepMind has entered the healthcare sector to tackle problems such?as predicting patient deterioration, AI-assisted radiology analysis, and drug discovery. Moreover, Google Cloud's AI solutions are enhancing healthcare by facilitating data interoperability and providing AI tools for advanced analytics and machine learning applications.

2. IBM Watson

IBM Watson has been a formidable player in the AI space, offering AI solutions to help healthcare organizations analyze big data to improve patient outcomes, streamline clinical trials, and make more informed decisions. Watson's capabilities in natural language processing and machine learning have been utilized in various healthcare applications including drug discovery and cancer treatment.

3. Microsoft

Microsoft has been making significant strides with its AI initiatives. Its healthcare cloud platform, Azure, provides a range of AI-enabled tools and services that help healthcare organizations to improve operations and offer better patient care. Moreover, projects like InnerEye, which is focused on utilizing AI for medical imaging, demonstrate Microsoft's commitment to fostering innovation in healthcare.

4. OpenAI

OpenAI, the organization behind ChatGPT, is also venturing into healthcare. Given their expertise in generative AI, they are working towards developing models that can assist in various facets of healthcare including research, data analysis, and possibly even personalized healthcare advice in the future.

5. NVIDIA

NVIDIA, traditionally known for its graphics processing units, has emerged as a significant player in AI, offering platforms and tools that assist in deep learning and AI applications in healthcare. Their Clara healthcare application framework is designed to bring AI to medical imaging and genomics, accelerating the development and deployment of AI in healthcare.

How Can AI Be Integrated?

As we delve deeper into the intricacies of AI integration in healthcare, it becomes apparent that a synergetic approach is inevitable. Noteworthy tech giants such as Google's DeepMind, IBM Watson, and NVIDIA have progressively marked their territory in this blossoming landscape. Through extensive partnerships and collaborations, these big players are being utilized in each of the key arenas we are about to explore. Their technological prowess is carving out new pathways, bridging gaps between biotech, medtech, diagnostics, and SaaS solutions. These alliances foster innovation and escalate the pace of advancements, making the integration of AI in healthcare not only a possibility but a transformative reality. Let's delve into the specifics of how AI can be intricately woven into each segment, catalyzing a revolution that promises optimized outcomes and streamlined processes.

Biotech and Pharma

• AI-Enabled Drug Discovery: Enhancing the identification and separation of molecules for cost-effective cell and gene therapies.

• Manufacturing Enhancement: Shifting from batch to continuous manufacturing to streamline processes and reduce costs.

• Clinical Trial Optimization: Utilizing AI to refine and accelerate pre-clinical and clinical trial phases.
• Predictive Analytics: Leveraging AI for predictive analytics, enabling more accurate forecasts of drug effectiveness and patient outcomes.
• Personalized Medicine: Facilitating the development of personalized medicine strategies through AI-driven data analysis, fostering treatments tailored to individual patient profiles.

Medtech

• Medical Imaging: Leveraging AI for in-depth analysis of medical images, ensuring more accurate and quicker diagnoses.
• Surgical Robotics: Implementing AI in surgical robotics for enhanced precision and efficiency during procedures.
• Virtual Reality (VR) Guidance: Utilizing VR headsets integrated with AI to assist surgeons with better visualization and guidance.
• Advanced Detection Tools: Developing AI-guided tools like enteroscopes and ultrasounds for early and precise detection of conditions.
• Remote Monitoring: Facilitating remote monitoring of patients through AI-powered tools, promoting timely interventions and better management of chronic conditions.

Diagnostics

• Wearable Devices: Introducing wearable devices capable of real-time monitoring for conditions like sepsis and epilepsy.
• Computer Vision in Cancer Detection: Utilizing computer vision for early and precise detection of skin cancers.
• Remote ECG Analysis Tools: Implementing AI-powered ECG analysis tools for quick and remote diagnoses of heart issues.
• Dementia Diagnostics: Enhancing dementia diagnostics through AI, allowing for early detection and more effective management.
• Lab Automation: Integrating AI in laboratories for automated data analysis and report generation, improving efficiency and accuracy.

SaaS

• Versatile Applications: Creating diverse applications ranging from fitness apps to bioinformatics platforms with the aid of large language models (LLMs).
• Automated Transcription: Developing AI-based transcription software to streamline medical documentation processes.
• Medical Record Enhancement: Revamping medical record management through AI, facilitating swift and accurate analysis of extensive patient histories.
• Telemedicine Integration: Incorporating AI into telemedicine platforms for improved service delivery and patient engagement.
• Predictive Health Analytics: Leveraging AI for predictive health analytics in SaaS platforms, enabling personalized health insights and recommendations.

Exit Opportunities: Positioning for a Profitable Future

In the ever-evolving landscape of AI-enabled healthcare technologies, recognizing viable exit opportunities is an essential component of a well-rounded investment strategy. While Initial Public Offerings (IPOs) remain a significant avenue, we foresee a notable uptick in merger and acquisition (M&A) activities as a promising trend for substantial returns on investment.

In a scenario reminiscent of the pharmaceutical industry's trajectory, we predict a burgeoning space where the giants of various sectors — be they hospitals, pharma/biotech companies, or medtech corporations — will be on the lookout to acquire startups that have carved a niche of innovation and success. These startups, hailed as winners in this dynamic space, would be recognized for their trailblazing approaches and their potential to further the goals of these established entities.

At Intelligence Ventures, we firmly believe that we are on the cusp of an era where technology is still in its nascent stage, offering a fertile ground of opportunities. By steering investments towards startups with a high potential of being acquired by industry behemoths, we pave the way for lucrative exits that promise substantial gains.

In this regard, our strategy revolves around nurturing startups to a point where they not only align with the acquisition goals of these major players but also stand as frontrunners in the innovation race. The alignment of these young ventures with larger, established entities can serve as a catalyst, propelling the sector into an era marked by heightened innovation and sustained growth.?

Through meticulous strategizing and foresight, we endeavor to position our investments in a manner that makes them attractive prospects for acquisitions, setting the stage for a profitable exit strategy that benefits all stakeholders involved.

Section 2: How Intelligence Ventures Thinks About Portfolio Construction

The Rationale Behind Our Investment Strategy?

In the rapidly evolving landscape of healthcare and AI, Intelligence Ventures stands as a beacon of innovation and foresight. Our investment strategy is finely tuned to identify and nurture companies that are pioneering change at the intersection of artificial intelligence and healthcare. We focus on both pre-seed and seed stages, as well as Series A companies, facilitating their growth and fostering the next generation of industry leaders. Our investment philosophy is rooted in a deep understanding of the market dynamics and a clear vision of the future trajectories in the sector.

A Balanced Portfolio: FDA Regulated and Non-FDA Regulated Technologies

In the dynamic landscape of healthcare investments, Intelligence Ventures prides itself in steering a prudent course, offering a portfolio that captures the quintessence of balanced risk and substantial reward. Our strategy leverages the immense potentials of FDA regulated technologies while counterbalancing the inherent risks through judicious investments in the burgeoning non-FDA regulated sectors, notably tech.

High Risk, High Reward: The Realm of FDA Regulated Technologies

Investing in FDA regulated technologies invariably implies entering a domain characterized by both colossal potential rewards and significant risks. These technologies encompass pharmaceutical drugs, biologics, and medical devices - spheres noted for their intensive capital and time requirements. The journey from concept to FDA approval is typically a decade-long venture, necessitating an average investment of $2.6 billion. Furthermore, the path is fraught with uncertainty, with a mere 12% of candidate medicines advancing past Phase I clinical trials to attain FDA endorsement. [2]

However, the rewards for navigating this precarious pathway successfully can be staggering. A beacon of success in this domain is Humira, a pharmaceutical marvel often likened to a "swiss army knife" of drugs due to its extensive applicability in treating a plethora of diseases. In 2021 alone, it generated a staggering $20.7 billion in revenues, representing the monumental gains achievable in this sector. [3]

For investors, it translates to a highly volatile yet potentially lucrative venture, offering rewards that are as monumental as the associated risks. At Intelligence Ventures, we are attuned to these dynamics, aiming to facilitate avenues where limited partners (LPs) can reap the high returns associated with FDA regulated technologies, whilst enjoying the stability offered by non-FDA regulated sectors.

Non-FDA Regulated Technologies: Rapid Commercialization in a Crowded Market

The non-FDA regulated sector presents an entirely different investment narrative, markedly distinguished by its quick turnaround time. With the ability for products and solutions to move from conceptualization to commercialization in an incredibly short span, this segment is appealing for its potential for rapid revenue generation. Such expedited pathways to market inevitably attract a plethora of players, resulting in a highly crowded space. The market brims with software companies leveraging AI to revolutionize healthcare, emphasizing the sector's dynamic nature and the comparatively lower barrier to entry.

Yet, this bustling landscape shifts the investment focus from lengthy regulatory approvals to other crucial factors. Here, the story is less about the challenging journey to approval (at least in the early venture days, anyways) and more about market penetration, differentiation, and above all, management's ability to execute efficiently. The question for investors morphs from "Will this get approved?" to "Can this stand out and deliver in a crowded market?"

Harnessing the Best of Both Worlds: The Intelligence Ventures Approach

At Intelligence Ventures, our vision is to craft a portfolio that encapsulates the best of both worlds, offering a blend that is not just balanced but optimized to deliver maximum value. We believe in fostering a milieu where investors can appreciate the high-yield potentials of FDA regulated technologies while enjoying consistent returns from the vibrant non-FDA regulated sector.

By offering a curated blend of both, we aspire to carve out a pathway to substantial returns, fostering a portfolio where the risk/return ratio is not just attractive but epitomizes a harmonious blend of stability and growth.

Section 3: Financial Insights from Intelligence Ventures

*In this critical section, we delve deep into the financial structure and projections that govern the operations of Intelligence Ventures. It gives a glimpse into our strategic financial planning, aiming to facilitate innovation in the AI and healthcare domains within the US. We break down our financial approach into several components:

The Financial Model: A Brief Overview?

With an earmarked fund size of $25 million, Intelligence Ventures is structured to nurture innovation over a 10-year investment window. The fund emphasizes a diversified portfolio, with investments spread across Pre-Seed, Seed, Series A, and Series B stages.

Here's a concise overview of our financial blueprint:

• Fund Size: $25,000,000
• Investment Window (Years): 10
• Annual Management Fees: 2%
• Carry: 20%

Understanding the Financial Math: ROI, Growth Metrics, and Projections

An essential part of our strategy is to decipher the underlying financial math that guides our investment decisions. We are focused on maximizing???? ?the Return on Investment (ROI) while offering an attractive IRR ?????by structuring a well-balanced, diversified portfolio supported by???? ?iterative financial forecasting???? . All models are wrong, but some are useful. This diligent, structured ?????approach maximizes our probability of returning capital to our LPs.????

Risk Mitigation and Financial Health: How We Secure Investments

At Intelligence Ventures, we prioritize securing our investments through a structured risk mitigation strategy. This includes an in-depth analysis of potential market fluctuations, exit strategies, and ensuring an adequate buffer to safeguard the fund's health.

The financial metrics and calculations such as Net Present Value (NPV), Internal Rate of Return (IRR), and others offer insights into the financial health and potential growth trajectory of the fund.

Our management strategies are designed to secure investments by:

Ensuring a diversified portfolio to mitigate risks.

Adhering to a calculated and structured financial strategy to sustain in varied market conditions.

Leveraging AI and Machine Learning models to facilitate informed and intelligent investment decisions.

Section 4: Why Invest through Intelligence Ventures

Our Vision and Mission

In an era where innovation is paramount, Intelligence Ventures stands as a beacon of progress, nurturing the symbiotic relationship between artificial intelligence and healthcare. Since our inception in February, we have swiftly mobilized to embody our mission which is both simple and monumental: to foster the development and growth of startups that are steering a revolution in the healthcare sector.

In a short span of time, we have grown into a robust team of 7 professionals, having engaged with 60+ startups that align with our investment thesis and forging connections with over 60 investors to syndicate deals with. Our efforts have also been bolstered by an exceptional advisory board consisting of 5 industry stalwarts, bringing a wealth of knowledge and expertise to the table. This dynamic approach not only provides financial backing but also fosters a realm of scientific and technical guidance, a trait that distinguishes us in the venture capital landscape.

We envision a future where healthcare is driven by data and artificial intelligence, making diagnoses more accurate, treatments more effective, and healthcare systems more efficient. As pioneers in this venture, we are dedicated to removing the computational bottlenecks that hinder the progress of medical advancements. Our focus transcends beyond mere financial investments, cultivating a space where innovative ideas are transformed into life-saving solutions, a journey we have enthusiastically embarked upon, making significant strides with remarkable momentum.

AI Health Fund I: Fostering the Next Generation of Innovations

At the heart of our venture lies the AI Health Fund I, a carefully curated fund focused on catalyzing innovation at the junction of AI and healthcare. We identify and back companies that aim to break the computational barriers in drug development, clinical trials, and medical diagnostics. By fueling these pioneers, we are fostering a new generation of industry leaders, adept and driven to steer healthcare into an unprecedented future.

?The Fund is industry vertical agnostic, making intelligent investments in biotech, pharma, medtech, and diagnostics, with a belief in the transformative power of generative AI and ML models. Our approach is to unlock the untapped potential within these sectors, providing the necessary capital and support to throttle innovation and accelerate growth.

A Glimpse into Our Strategy: How We Identify and Nurture Potential Leaders

Our strategy is rooted in a deep understanding of the AI and healthcare sectors, a synergy of science and business acumen. We employ a meticulous approach to identify potential leaders, analyzing not only their technological capabilities but also their vision, adaptability, and determination to create a lasting impact.

Once identified, these potential leaders are nurtured through a tailored strategy that encompasses financial backing, mentorship, and guidance to traverse the complex landscape of the healthcare industry. Our commitment extends to fostering an environment where these companies can thrive, ensuring they have the tools and resources necessary to become flag-bearers of innovation.

Our network within the industry allows us to foster collaborations, creating synergies that amplify the growth and influence of the companies we back. With Intelligence Ventures, these burgeoning companies find not just an investor, but a partner devoted to realizing a vision of healthcare that is not only more efficient but also more compassionate and inclusive.

Section 5: Tips for LPs

?Evaluating Prospects: What to Look for in a Potential Investment

In the dynamic landscape of venture capitalism, the opportunities for investments are ample. However, when contemplating opportunities to become an LP in a VC fund, certain key aspects should guide your decisions to ensure a lucrative and sustainable partnership. Here are a few pivotal factors to consider:

1. Access to Exclusive Deals: When in the market to become an LP, it's vital to align with a VC that has its finger on the pulse of the industry. Seek out ventures that are actively engaged in tech transfer offices, attending conferences, and networking extensively with other VCs. A proactive approach like this not only facilitates access to the most exclusive deals but also fosters a rich environment of innovation and collaboration. Intelligence Ventures, for instance, has established a robust network through avenues such as their widely recognized publication, 'The Intelligence Report', which attracts a significant number of inbound requests from potential collaborators.
2. Multi-disciplinary Expertise: In a multidisciplinary field such as the intersection of AI and healthcare, the composition of the team managing the VC fund is critical. Opt for a fund that embodies a diverse team, boasting expertise in various domains such as science, technology, and entrepreneurship. A team that can critically assess potential investments from different angles ensures a holistic approach to nurturing portfolio companies, thereby securing successes that reverberate back positively to the LPs. For instance, our team at Intelligence Ventures is a medley of scientists, software engineers, and seasoned entrepreneurs who have successfully exited companies, ensuring a comprehensive due diligence process that aligns with the interests of both the portfolio companies and the LPs.
3. Research-Driven Insights: A VC that values research and regularly publishes insightful reports indicates a keen understanding of the market dynamics and trends. These publications can be a valuable resource in gauging the pulse of the industry, helping LPs to stay informed and make well-judged investment decisions.
4. Alignment with Investment Thesis: Ensure that the fund's investment thesis resonates with your vision and objectives. A clear and focused investment thesis can be a beacon, guiding the fund to invest in companies that are truly innovative and have the potential to revolutionize the industry, promising rewarding returns for the LPs.
5. Agility and Nimbleness: In the world of investment, time often equates to opportunity. Being part of a smaller fund, like Intelligence Ventures, grants a distinct advantage of agility and nimbleness. The fund can quickly adapt to new situations, devoid of any bureaucratic red tape, allowing for rapid movement and decision-making. Furthermore, the smaller check sizes mean the ability to squeeze into deals that might already be closed, helping to oversubscribe and yet being a part of the success story - a maneuver that larger funds might find challenging to execute. This nimble approach not only facilitates access to lucrative opportunities but also fosters a dynamic and responsive investment environment, promising rewarding outcomes for the LPs.

By considering these factors, LPs can forge partnerships that are not only lucrative but also aligned with the pioneering spirit of innovation in the fields of artificial intelligence and healthcare.

Risk Mitigation: How to Balance Risks and Rewards

In the ever-evolving landscape of venture capitalism, especially at the junction where artificial intelligence meets healthcare, effective risk mitigation forms the backbone of any successful investment strategy. Here are some strategic approaches to balance the scales of risks and rewards:

1. Diversification: One cardinal principle of risk mitigation is diversification. In an industry as vast and dynamic as healthcare, it is prudent to not put all your eggs in one basket. A well-rounded strategy would include a spread across various verticals including biotech, pharma, medtech, diagnostics, and SaaS. Moreover, considering the intricate regulatory landscape, it is sensible to balance investments between FDA-regulated entities and those that are not, to safeguard against unforeseen regulatory hurdles and maintain a steady growth trajectory. By steering a diversified portfolio, you not only spread the risk but also create avenues for potential high rewards, leveraging the strengths and opportunities present in each vertical.
2. Due Diligence: For a multidisciplinary field like the convergence of artificial intelligence and healthcare, due diligence is not just a process, but a necessity to unearth and nurture potential industry leaders. It is essential that the fund leverages a proven due diligence process, augmented to cater to the unique demands of this field. At Intelligence Ventures, we have adapted a tried-and-tested due diligence process that has been successful for previous funds, fine-tuning it to include in-depth reviews from a panel of experts consisting of scientists, clinicians, and technological mavens. This multi-faceted approach ensures that potential investments are scrutinized from various perspectives, thus fostering a healthy portfolio that is geared towards both innovation and growth.
3. Advisory Input: Leveraging the wisdom and insights of an adept advisory board is a crucial aspect of risk mitigation. An advisory board that is rich in experience and expertise can provide invaluable guidance, helping to steer the fund in the right direction and making informed decisions. Their seasoned perspectives can be a beacon, helping to navigate the complex waters of investment in the artificial intelligence and healthcare sectors, ensuring a rewarding and sustainable journey for both the fund and the LPs.

By incorporating these strategies, LPs can be assured of a well-rounded approach to investment, where risks are meticulously mitigated, paving the way for promising rewards and fostering a culture of collaborative growth and innovation.

Conclusion

?The convergence of artificial intelligence and healthcare stands as a beacon heralding a new dawn in medical innovation. The journey that beckons is one filled with untapped potential and unprecedented advancements. As we navigate this promising terrain, we offer this handbook as a guide to LPs keen on making informed decisions in the investment space of AI-enabled healthcare technologies. At this juncture, Intelligence Ventures stands as a reliable partner, fostering the next wave of groundbreaking companies that aim to redefine the healthcare sector.

The Road Ahead: Predictions for the Future

We find ourselves at a remarkable juncture where AI has achieved a critical mass, especially with the advent of generative AI. This technological surge is not a wave to ride, but a seismic shift poised to revolutionize the healthcare landscape. It is a transition from conventional methods to a future laden with innovations that are both transformative and inclusive.

Healthcare executives, who are already welcoming the integration of this technology, signal a sector ripe for a flurry of innovation. The market will undoubtedly see a surge in the number of companies entering this space, bringing with them a multitude of investment opportunities. In this vibrant ecosystem, venture funds like Intelligence Ventures hold the mantle of distinguishing the real trailblazers from the crowd – an endeavor to pinpoint the 'needle in the haystack', so to speak.

As we anticipate a future vibrant with innovations, LPs stand at a vantage point, holding the golden ticket to be a part of this transformative journey. It is a call to seize this opportunity, to invest in a sector that promises not just substantial returns, but a chance to shape the healthcare of tomorrow.

Building a Healthier Tomorrow: A Call to Action for LPs

The pathway to a healthier tomorrow is both a venture and a responsibility. As we set our sights on this future, the role of LPs transcends being mere investors. It is a clarion call to be pioneers, to foster and fuel the innovations that stand to redefine healthcare.

The potential avenues for investment are manifold, spanning across a spectrum of industry verticals that include biotech, pharma, medtech, diagnostics, and SaaS. By aligning with a venture capital fund that epitomizes the spirit of innovation and collaboration, LPs are presented with a unique opportunity to influence the trajectory of healthcare, to usher in a new era of advancements that are data-driven, efficient, and poised to reshape the healthcare narrative globally.

Call to Action

In this promising narrative, we extend an invitation to LPs to join us at the helm of this revolutionary journey. Align with Intelligence Ventures and be part of a consortium that stands at the frontier of healthcare innovation, a movement aiming to redefine the contours of healthcare through the power of artificial intelligence.

We beckon you to join this collaborative effort, to foster a future where healthcare is not only advanced but also inclusive and accessible to all. Let us forge a partnership that seeks to carve a niche in history, steering the world towards a healthier, brighter, and more promising tomorrow.

Let's seize this moment, and together, forge a legacy that stands as a beacon of innovation and human ingenuity in healthcare. Let's create history, together.

More about Intelligence Ventures

We are an emerging venture capital firm dedicated to cultivating innovation at the intersection of artificial intelligence and healthcare within the United States. Our commitment lies in the strategic investment and nurturing of pre-seed, seed, and Series A companies, fueling their growth and fostering the next generation of industry leaders.

Our first fund, AI Health Fund I, will be focused on companies that use artificial intelligence to increase efficiencies and/or solve computationally intractable problems that place a ceiling on our ability to develop new drug s, advance them through clinical trials, and ultimately diagnose and treat patients. We are industry vertical agnostic and believe that generative AI and more specific ML models can be used to accelerate innovation in biotech, pharma, medtech, and diagnostics.

For more information, visit our website at www.intelligencevc.com or reach out to [email protected] for any inquiries. Be sure to follow us on LinkedIn and Twitter , and subscribe for further installments of The Intelligence Report .

References

[1] Morgan Stanley. (2023, August 15). How Artificial Intelligence Could Reshape Health Care. Retrieved from [https://www.morganstanley.com/ideas/ai-in-health-care-forecast-2023 ].

[2] Stow, T. (2015, August 24). The drug development and approval process is about much more than the final “okay”. PHRMA. Retrieved from [https://www.phrma.org/the-drug-development-and-approval-process-is-about-much-more-than-the-final-okay ].

[3] Dunleavy, K. (2022, February 2). Humira rings up $20.7B in 2021, but AbbVie still mum on post-biosimilar expectations. Fierce Pharma. Retrieved from [https://www.fiercepharma.com/financials/humira-rings-up-20-7b-2021-but-abbvie-still-mum-post-biosimilar-expectations ].

[4] NapSaga (2023, May 1). Chat GPT: Achieving 100 Million Users in Just 2 Month — A Deep Analysis. Artificial Intelligence in Plain English. Retrieved from [https://ai.plainenglish.io/chat-gpt-achieving-100-million-users-in-just-2-month-a-deep-analysis-a453e6f85acf ].

[5] Nissinoff, D. (2023, August 11). The Role of Artificial Intelligence in Accelerating the Pharma Clock: Revolutionizing Drug Discovery and Development. The Intelligence Report. Retrieved from [https://www.dhirubhai.net/pulse/role-artificial-intelligence-accelerating-pharma-clock-doug-nissinoff ].

[6] Nissinoff, D. (2023, August 17). Revolutionizing Small Molecule Manufacturing with the AI/ML Paradigm Shift: Producing the 'Golden Batch'. The Intelligence Report. Retrieved from [https://www.dhirubhai.net/pulse/revolutionizing-small-molecule-manufacturing-aiml-shift-nissinoff ].

[7] Nissinoff, D. (2023, August 31). AI-Enabled Medical Devices: We See Opportunity. The Intelligence Report. Retrieved from [https://www.dhirubhai.net/pulse/ai-enabled-medical-devices-we-see-opportunity-doug-nissinoff ].

Legal Disclaimer

This document is intended for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor does it constitute an offer to provide investment advisory or other services by Intelligence Ventures.

No reference to any specific security constitutes a recommendation to buy, sell, or hold that security or any other security. Nothing in this document shall be considered a solicitation or offer to buy or sell any security, future, option, or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction.

Investments in venture capital funds are speculative and involve a high degree of risk. Investors could potentially lose all or a substantial portion of their investment. Past performance is not indicative of future results. Nothing contained herein constitutes investment, legal, tax, or other advice nor is it to be relied on in making an investment or other decision.

Prospective investors should make their own investigations and evaluations of the information contained herein. Each prospective investor should consult its own attorneys, business advisors, and tax advisors as to legal, business, tax, and related matters concerning the information contained herein.

Further, the information contained herein may include estimates and forward-looking statements which may prove to be substantially different from actual results. Intelligence Ventures expressly disclaims any responsibility to update such information, opinions, estimates, and forward-looking statements.

*These statements reflect management’s current views based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.